Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6970173 | 0.98 | CYP19A1 (0.47) | CYP19A1ALDH1A1GAAMAPTRAB9A | |
| SCHEMBL4194796 | 0.82 | CA2 (0.46) | ALDH1A1GAARAB9ANPC1CA2 | |
| SCHEMBL10750108 | 0.80 | CYP19A1 (0.52) | CYP19A1ALDH1A1GAAMAPTRAB9A | |
| SCHEMBL48554 | 0.78 | AKR1B1 (0.61) | CYP19A1ALDH1A1GAAMAPTCA2 | |
| SCHEMBL8040203 | 0.78 | CYP19A1 (0.50) | CYP19A1ALDH1A1GAAMAPTRAB9A | |
| SCHEMBL9706507 | 0.77 | FFAR1 (0.49) | RAB9ANPC1LOXL2SMN1; SMN2HDAC6 | |
| Hydrochloric Acid SCHEMBL367129 | 0.76 | AKR1B1 (0.58) | CYP19A1ALDH1A1GAAMAPTCA2 | |
| Potassium Ion SCHEMBL17653817 | 0.76 | CYP19A1 (0.48) | CYP19A1ALDH1A1GAAMAPTRAB9A | |
| SCHEMBL5943952 | 0.76 | CYP19A1 (0.48) | CYP19A1ALDH1A1GAAMAPTRAB9A | |
| SCHEMBL11400677 | 0.76 | LOXL2 (0.42) | CYP19A1ALDH1A1GAAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| CN-113997650-A | Multilayer structure assembly with force-induced responsiveness | 厦门天策材料科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113978071-A | Multilayer structure assembly | 翁秋梅 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| CN-111378144-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111134409-A | Self-adaptive clothes | 翁秋梅 | 2020-05-12 | — | — | CN | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| US-5232978-A | 1-(2-arylethyl)-pyrrolidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-08-03 | — | — | US | disclosed |
| EP-0483580-A2 | 1-(2-Arylethyl)-pyrrolidine | MERCK PATENT GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
| US-4882342-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | CYP19A1 133/4885ALDH1A1 323/4885GAA 2909/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | CYP19A1 1940/4885ALDH1A1 852/4885GAA 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.